Olr1704 inhibitors are a class of chemical compounds that specifically target and modulate the activity of the Olr1704 receptor, a member of the olfactory receptor family. These receptors are typically G-protein-coupled receptors (GPCRs) located in the olfactory epithelium, where they play a critical role in the detection and transduction of odorant signals. The Olr1704 receptor, like other members of the olfactory receptor family, binds to specific molecules, or ligands, in the environment, triggering a conformational change that initiates a cascade of intracellular signaling pathways. The modulation of Olr1704 by specific inhibitors can significantly impact the receptor's ability to bind to its natural ligands, thereby altering the downstream signaling pathways and potentially affecting the overall olfactory perception. These inhibitors often exhibit a high degree of selectivity for Olr1704, which is crucial for understanding the intricate molecular mechanisms governing olfactory signal transduction.
The design and synthesis of Olr1704 inhibitors involve a detailed understanding of the receptor's structure, particularly the binding site where the inhibitors interact with the receptor. This often requires the use of advanced techniques such as molecular docking, computational modeling, and structure-activity relationship (SAR) studies to predict and optimize the interaction between the inhibitors and the receptor. The specificity of these inhibitors is determined by their ability to bind precisely to the active site of Olr1704 without affecting other related receptors, which is critical for studying the unique functional role of Olr1704 in olfactory signaling. Research into Olr1704 inhibitors not only provides insights into the fundamental biology of olfactory receptors but also contributes to the broader understanding of GPCR modulation, which has implications across various fields of chemical and molecular biology. The ongoing development of these inhibitors is a testament to the complexity and sophistication of receptor-ligand interactions within the olfactory system.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase, potentially affecting proteins in leukemia-associated pathways. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates ubiquitin ligase activity, potentially affecting protein degradation pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases, potentially influencing proteins in cell signaling pathways. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Modulates immune response and inhibits angiogenesis, potentially influencing proteins in these pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, potentially affecting proteins in cell signaling and growth pathways. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Inhibits histone deacetylases, potentially affecting gene expression and proteins involved in chromatin remodeling. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGF receptors, potentially affecting proteins involved in angiogenesis and tumor growth. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted tyrosine kinase inhibitor, potentially influencing proteins involved in angiogenesis and tumor growth. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling. | ||||||